venture capital firm
Feb 14, 2019
Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets
Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The idea is to take its major programs into IND-enabling studies for Aspartylglucosaminuria (AGU) and a rare form of Charcot-Marie Tooth disease with...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
